Percheron Therapeutics Limited has released a press release.
ATL1102 Toxicology Protocol submitted to US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Investor Presentation
- Positive PDCO opinion and A$20m Placement
- Positive feedback received on Paediatric Investigation Plan
- New data supports ATL1102s broader clinical potential
- ANP to present new proteomics data at WMS Congress 2021
Later from Percheron Therapeutics
- Positive UK PIP Decision & PDCO opinion ratification by EMA
- Annual General Meeting Presentation
- Entitlement Offer Results
- Quarterly Report and Appendix 4C
- Dosing commenced in MCRI collaboration animal study
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics